正康國際 ZKIN 深 滬
等待開盤 03-26 09:30:00 美东时间
1.6974
+0.052
+3.19%
華盛通- 最 高1.7322
- 今 開1.7322
- 成交量 2709股
- 最 低 1.67
- 昨 收 1.645
- 總市值 2931.80万
- 52周最高 4.47
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 0.82
- 委 比 18.60%
- 總股本 1727.23万
- 歷史最高 112.00
- 量 比 0.07
- 振 幅 3.78%
- 歷史最低 1.10
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sranan Gold Extends Randy’s Pit Mineralization Along Poeketi Shear Zone
The latest update is out from Peak Minerals Ltd. ( ($TSE:SRAN) ). Sranan Gold C...
今天 02:10
G R Infraprojects offloads three highway subsidiaries to Indus Infra Trust
G R Infraprojects Ltd. ( ($IN:GRINFRA) ) has provided an announcement. G R Infr...
今天 01:16
Shree Digvijay Cement Posts Analyst Call Recording for Investors
Shree Digvijay Cement Co. Ltd. ( ($IN:SHREDIGCEM) ) has shared an announcement....
今天 01:14
Mokingran Jewellery Sells Majority Stake in Shenzhen E-Commerce Unit
An update from Mokingran Jewellery Group Co Ltd Class H ( ($HK:2585) ) is now a...
03-25 22:08
Clarity Pharmaceuticals signs copper-64 manufacturing supply agreement with Theragenics; agreement effective March 25, 2026
Clarity Pharmaceuticals signs copper-64 manufacturing supply agreement with Theragenics; agreement effective March 25, 2026 Clarity Pharmaceuticals signed a large-scale Manufacturing Supply Agreement with Theragenics for copper-64. The agreement covers Theragenics’ 134,000 square foot production fac
03-25 21:04
Critical Infrastructure Technologies signs 50-50 JV with Juno Industries; Juno contributes $450,000
Critical Infrastructure Technologies signs 50-50 JV with Juno Industries; Juno contributes $450,000 Critical Infrastructure Technologies signed a 50/50 joint venture agreement with Juno Industries to co-develop and commercialize an Arctic-ready version of the company’s Nexus platform, branded the “P
03-25 21:02
Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing
03-25 20:02
Hyfusin Group FY2025 profit drops 40.8% to HK$101 million; revenue slips 1.2% to HK$898 million
Hyfusin Group FY2025 profit drops 40.8% to HK$101 million; revenue slips 1.2% to HK$898 million FY2025 earnings per share fell 37.14% to 11.05 HK cents. FY2025 profit for the year attributable to owners dropped 40.8% to HK$101 million on lower gross profit. FY2025 profit before income tax expense sl
03-25 19:53
EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
Co-Diagnostics ships PCR Pro and TB test kits to India, advancing clinical studies as the WHO backs NPOC diagnostics.
03-25 19:46
ARM Stock's Momentum Score Leaps Fueled By In-House AGI Chip Ambitions
Nvidia & Apple partner ARM sees its Momentum score double to 52.09 amid a pivot to a $15B in-house AI chip market.
03-25 19:39
